Comparative effectiveness and tolerability of targeted agents combined with chemotherapy in patients with HER2-positive gastroesophageal cancer: A network meta-analysis
Conclusion: TraD had relative advantages as the second- or third-line therapy and in the IHC3 + population. PerTraChemo is a potential first-line therapy, but it requires further confirmation because the JACOB phase III clinical trial failed to confirm the superiority of PerTraChemo over TraChemo with regard to OS.
Source: The Saudi Journal of Gastroenterology - Category: Gastroenterology Authors: Yin-Hong Yan Xiao-Yi Lei Wei-Ping Hu Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Databases & Libraries | Gastric (Stomach) Cancer | Gastroenterology | HER2 | Herceptin | Middle East Health | Saudi Arabia Health